JP2012517241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517241A5 JP2012517241A5 JP2011550213A JP2011550213A JP2012517241A5 JP 2012517241 A5 JP2012517241 A5 JP 2012517241A5 JP 2011550213 A JP2011550213 A JP 2011550213A JP 2011550213 A JP2011550213 A JP 2011550213A JP 2012517241 A5 JP2012517241 A5 JP 2012517241A5
- Authority
- JP
- Japan
- Prior art keywords
- sample
- bcl
- gene
- patient
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 claims 125
- 238000000034 method Methods 0.000 claims 60
- 206010028980 Neoplasm Diseases 0.000 claims 38
- 210000001519 tissue Anatomy 0.000 claims 32
- 108090000623 proteins and genes Proteins 0.000 claims 29
- 239000012530 fluid Substances 0.000 claims 24
- 201000011510 cancer Diseases 0.000 claims 19
- 238000007901 in situ hybridization Methods 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 13
- 239000002853 nucleic acid probe Substances 0.000 claims 13
- 102000051485 Bcl-2 family Human genes 0.000 claims 12
- 108700038897 Bcl-2 family Proteins 0.000 claims 12
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 10
- 230000003321 amplification Effects 0.000 claims 10
- 238000003018 immunoassay Methods 0.000 claims 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 6
- 206010003445 Ascites Diseases 0.000 claims 6
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 6
- 210000001185 bone marrow Anatomy 0.000 claims 6
- 210000004556 brain Anatomy 0.000 claims 6
- 210000004072 lung Anatomy 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 210000005259 peripheral blood Anatomy 0.000 claims 6
- 239000011886 peripheral blood Substances 0.000 claims 6
- 238000003752 polymerase chain reaction Methods 0.000 claims 6
- 210000002700 urine Anatomy 0.000 claims 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 5
- 206010041067 Small cell lung cancer Diseases 0.000 claims 5
- 230000000692 anti-sense effect Effects 0.000 claims 5
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical group C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims 5
- 229950004847 navitoclax Drugs 0.000 claims 5
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 5
- 206010006223 Breast discharge Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 3
- 208000002151 Pleural effusion Diseases 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 230000002596 correlated effect Effects 0.000 claims 3
- 239000000284 extract Substances 0.000 claims 3
- 210000000416 exudates and transudate Anatomy 0.000 claims 3
- 210000001165 lymph node Anatomy 0.000 claims 3
- 238000002493 microarray Methods 0.000 claims 3
- 210000002445 nipple Anatomy 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 230000004544 DNA amplification Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15174909P | 2009-02-11 | 2009-02-11 | |
| US61/151,749 | 2009-02-11 | ||
| PCT/US2010/023818 WO2010093742A1 (en) | 2009-02-11 | 2010-02-11 | Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015162761A Division JP2016047044A (ja) | 2009-02-11 | 2015-08-20 | Ｂｃｌ−２ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012517241A JP2012517241A (ja) | 2012-08-02 |
| JP2012517241A5 true JP2012517241A5 (enExample) | 2013-03-28 |
Family
ID=42112120
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550213A Pending JP2012517241A (ja) | 2009-02-11 | 2010-02-11 | Ｂｃｌ−２ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物 |
| JP2015162761A Pending JP2016047044A (ja) | 2009-02-11 | 2015-08-20 | Ｂｃｌ−２ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015162761A Pending JP2016047044A (ja) | 2009-02-11 | 2015-08-20 | Ｂｃｌ−２ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9045800B2 (enExample) |
| EP (1) | EP2396427A1 (enExample) |
| JP (2) | JP2012517241A (enExample) |
| CN (1) | CN102388151A (enExample) |
| CA (1) | CA2751293A1 (enExample) |
| MX (1) | MX2011008488A (enExample) |
| WO (1) | WO2010093742A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107315088A (zh) * | 2012-05-10 | 2017-11-03 | 尤特罗皮克斯制药股份有限公司 | 对癌症的代理功能性诊断测试 |
| IN2014DN11205A (enExample) | 2012-06-20 | 2015-10-02 | Eutropics Pharmaceuticals Inc | |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| WO2015017788A1 (en) | 2013-08-01 | 2015-02-05 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
| AU2014342269B2 (en) | 2013-10-30 | 2020-02-27 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
| HK1247250A1 (zh) | 2015-01-12 | 2018-09-21 | Eutropics Pharmaceuticals, Inc. | 用於指导癌症治疗的内容相关的诊断测试 |
| JP6851978B2 (ja) | 2015-04-20 | 2021-03-31 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ミトコンドリアプロファイリングによるアルボシジブ応答の予測 |
| JP6510075B2 (ja) | 2015-05-18 | 2019-05-08 | トレロ ファーマシューティカルズ， インコーポレイテッド | バイオアベイラビリティが高いアルボシジブプロドラッグ |
| EP3331510A4 (en) | 2015-08-03 | 2019-04-03 | Tolero Pharmaceuticals, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| AU2017305508B2 (en) | 2016-08-05 | 2021-01-07 | The Regents Of The University Of Michigan | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| CA3047557A1 (en) | 2016-12-19 | 2018-06-28 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| TWI725488B (zh) | 2018-07-31 | 2021-04-21 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途 |
| CN114522167A (zh) | 2018-07-31 | 2022-05-24 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| EP3672594B1 (en) | 2018-07-31 | 2021-09-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| AU2019315466B2 (en) | 2018-07-31 | 2022-05-19 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| EP3758005A1 (en) * | 2019-06-24 | 2020-12-30 | Koninklijke Philips N.V. | Identification of the cellular function of an active nfkb pathway |
| WO2025136456A1 (en) * | 2023-07-14 | 2025-06-26 | Eil Therapeutics, Inc. | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8108820A (pt) | 1980-09-24 | 1982-08-24 | Cetus Corp | Processo e sonda de diagnostico |
| ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5756696A (en) | 1986-01-16 | 1998-05-26 | Regents Of The University Of California | Compositions for chromosome-specific staining |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
| US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
| US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
| US5231020A (en) | 1989-03-30 | 1993-07-27 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
| US5491224A (en) | 1990-09-20 | 1996-02-13 | Bittner; Michael L. | Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture |
| US5464746A (en) | 1991-12-17 | 1995-11-07 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives |
| US5424414A (en) | 1991-12-17 | 1995-06-13 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids |
| US6214986B1 (en) * | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| US6395472B1 (en) | 1999-02-05 | 2002-05-28 | Abbott Laboratories | Methods of utilizing the TT virus |
| US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
| US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
| US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
| US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
| CN1834261A (zh) * | 2005-11-15 | 2006-09-20 | 北京博奥生物芯片有限责任公司 | 基因分型芯片及其制备方法与应用 |
| US20080233567A1 (en) * | 2006-09-05 | 2008-09-25 | Murray William E | Companion diagnostic assays for cancer therapy |
| WO2008082643A2 (en) * | 2006-12-28 | 2008-07-10 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
| CN102203788B (zh) | 2008-10-31 | 2015-05-20 | Abbvie公司 | 用于装配成小组的癌细胞系以用于测试一种或多种药物组合物的功效的方法 |
| JP6812855B2 (ja) | 2017-03-10 | 2021-01-13 | Jnc株式会社 | ジアルキルアミノシランの製造方法 |
-
2010
- 2010-02-11 CA CA2751293A patent/CA2751293A1/en not_active Abandoned
- 2010-02-11 WO PCT/US2010/023818 patent/WO2010093742A1/en not_active Ceased
- 2010-02-11 MX MX2011008488A patent/MX2011008488A/es active IP Right Grant
- 2010-02-11 US US12/704,165 patent/US9045800B2/en not_active Expired - Fee Related
- 2010-02-11 CN CN2010800160886A patent/CN102388151A/zh active Pending
- 2010-02-11 JP JP2011550213A patent/JP2012517241A/ja active Pending
- 2010-02-11 EP EP10706075A patent/EP2396427A1/en not_active Withdrawn
-
2015
- 2015-04-06 US US14/679,889 patent/US20150211075A1/en not_active Abandoned
- 2015-08-20 JP JP2015162761A patent/JP2016047044A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012517241A5 (enExample) | ||
| JP2013500001A5 (enExample) | ||
| CN111662982B (zh) | 用于脑胶质瘤早期诊断和/或复发监测的生物标志物及其应用 | |
| RU2014120427A (ru) | Определение микрорнк в плазме для обнаружения ранних стадий колоректального рака | |
| RU2012127812A (ru) | Комбинированная терапия для лечения рака и диагностические анализы, используемые в комбинированной терапии | |
| JP2019150027A5 (enExample) | ||
| JP2014509515A5 (enExample) | ||
| EP2036987A1 (en) | Molecular markers for tumor cell content in tissue samples | |
| EP3186394A1 (en) | Treatment and detection of melanoma | |
| TWI682034B (zh) | 用於評估子宮內膜癌的發展風險或診斷子宮內膜癌的方法 | |
| TWI571514B (zh) | 評估罹患大腸直腸癌風險的方法 | |
| CN110592223B (zh) | 一种NSCLC的诊断和预后标记物hsa_circRNA_012515的应用 | |
| TWI598444B (zh) | 用以評估乳癌罹患風險之方法及基因標記 | |
| CN111315897B (zh) | 用于黑素瘤检测的方法 | |
| KR102241455B1 (ko) | 조기 간암 진단을 위한 엑소좀 유래 microRNA 바이오마커 및 그 용도 | |
| CN112813167B (zh) | 标志物linc01977及其应用 | |
| CN110577999A (zh) | 一种cxcr4作为胃癌预后评估生物标志物的应用及诊断试剂盒 | |
| CN116287180A (zh) | 检测标志物的试剂在制备用于诊断哮喘的试剂盒中的应用 | |
| CN118922561A (zh) | 肾癌诊断用尿液miRNA标志物、诊断试剂及试剂盒 | |
| EP2716767A1 (en) | Method for determining the prognosis of pancreatic cancer | |
| JP2014003925A (ja) | 予後不良の肺小細胞がんの検査方法及び治療手段 | |
| CN114032308A (zh) | Fam83a、kpna2、krt6a和ldha联合作为肺腺癌生物标志物的用途 | |
| US20150087549A1 (en) | Methods of using tissue biomarkers for indication of progression from barretts esophagus to esophageal adenocarcinoma | |
| US20120149027A1 (en) | Method for Determining the Risk of Metastasis as an Indicator for Diagnostic Imaging | |
| ES2856232A1 (es) | Biomarcadores para predecir la respuesta de un sujeto a una terapia con bcg, metodos y usos basados en los mismos |